Clinical trials: High Cardiovascular Risk
Cardiovascular Diseases, Acute Coronary Syndrome
Telemedicine in High-Risk Cardiovascular Patients Post-ACS
This is a non-CTIMP randomised controlled trial looking at the utilisation of telemedicine devices to provide remote, clinically necessary, diagnostic information, without the need for hospital attendance that patients will take…
- Trial name
- TELE-ACS (NCT05015634)
- Testing
- Active Arm, Control Arm
- Where
- United Kingdom
- Volunteers
- 337 people
- Sponsor
- Imperial College London
Carotid Artery Stenosis
GORE® Embolic Filter in Carotid Stenting for High Risk Surgical Subjects (EMBOLDEN)
Compare the 30-day safety and efficacy of the GORE® Embolic Filter used in conjunction with FDA-approved carotid stents to a performance goal obtained from carotid stent studies utilizing distal embolic protection.
- Trial name
- EMBOLDEN (NCT00766493)
- Testing
- GORE® Embolic Filter
- Volunteers
- 250 people
- Sponsor
- W.L.Gore & Associates
Hypertension
Evaluation of the Effect of Telmisartan on Blood Pressure Control of High Risk Patients
The study is designed to evaluate the effect of treatment with Micardis/MicardisPlus on blood pressure and its ability to reduce different indicated cardiovascular risk scores.
- Trial name
- NCT01108809
- Testing
- Telmisartan or Telmisartan and Hydrochlorthiazide
- Where
- 49 sites in Romania
- Volunteers
- 295 people
- Sponsor
- Boehringer Ingelheim
High-risk, Non-cardiovascular Surgeries
Esmolol for Treatment of Perioperative Tachycardia
The purpose of this study is to find out if Esmolol is a safe and effective alternative treatment compared to standard treatment using a long acting beta blocker drug, in controlling abnormal heart rate before, during and…
- Trial name
- NCT01208402
- Testing
- Esmolol
- Where
- 3 sites in United States
- Volunteers
- 76 people
- Sponsor
- Duke University
Coronary Artery Disease, Left Ventricular Dysfunction
Balloon Pump Assisted Coronary Intervention Study
This study will test the hypothesis that elective use of the Intra-Aortic Balloon Pump (IABP) in patients undergoing high-risk Percutaneous Coronary Intervention (PCI) will reduce the rate of in-hospital major adverse cardiac and…
- Trial name
- BCIS-1 (NCT00910481)
- Testing
- Intra-Aortic Balloon Pump
- Where
- United Kingdom
- Volunteers
- 301 people
- Sponsor
- British Cardiovascular Intervention Society
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma
This phase II trial studies the effect of selinexor when combined with carfilzomib, daratumumab, and dexamethasone in treating patients with high-risk multiple myeloma that has come back (recurrent) or has not responded to…
- Trial name
- NCT04756401
- Testing
- Carfilzomib, Daratumumab, Dexamethasone
- Where
- 4 sites in United States
- Volunteers
- 8 people
- Sponsor
- Academic and Community Cancer Research United
Obesity, Visceral, Cardiovascular Diseases
Impact of Liraglutide 3.0 on Body Fat Distribution
This study is a clinical study to investigate the efficacy of liraglutide compared to placebo in reducing visceral adiposity measured by MRI in overweight or obese subjects at high risk for cardiovascular disease after 40 weeks…
- Conditions
- Obesity, Visceral, Cardiovascular Diseases, Fat Disorder
- Trial name
- NCT03038620
- Testing
- Liraglutide
- Where
- United States
- Volunteers
- 235 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Hypercholesterolemia
Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia
Primary Objective: To demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab as add-on therapy to stable maximally tolerated daily statin therapy in comparison to ezetimibe 10 mg daily after 24…
- Trial name
- ODYSSEY EAST (NCT02715726)
- Testing
- Alirocumab, ezetimibe, atorvastatin
- Where
- 62 sites in China, India and 1 more
- Volunteers
- 615 people
- Sponsor
- Sanofi
Hypercholesterolemia
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)
Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9).
- Trial name
- NCT01644175
- Testing
- Alirocumab, Lipid-Modifying Therapy (LMT)
- Where
- 76 sites in United States
- Volunteers
- 316 people
- Sponsor
- Sanofi
Hypertension
Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension
A comparison study of two combination drugs, amlodipine/benazepril and benazepril/HCTZ to evaluate the effectiveness of the combination on reducing heart disease and death in a high risk hypertensive population.
- Trial name
- ACCOMPLISH (NCT00170950)
- Testing
- Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1, Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2, Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter
- Where
- 5 sites in United States, Denmark and 3 more
- Volunteers
- 11,506 people
- Sponsor
- Novartis
Coronary Artery Disease
On Versus Off Pump Myocardial Revascularization Study
Compare completeness and modality of revascularization, operative and postoperative results and 1 year clinical outcomes in unselected high risk patients referred for primary coronary artery bypass surgery.
- Trial name
- On-Off (NCT01290952)
- Testing
- Off-pump bypass surgery, On-pump bypass surgery
- Where
- 8 sites in Italy, Switzerland
- Volunteers
- 411 people
- Sponsor
- Medtronic Italia
Myeloma, Plasma-Cell, Myeloma-Multiple
Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma
Background: Cancer development is associated with problems in immune system functions, which prevent the body from attacking and destroying the abnormal cells that lead to tumor growth.
- Conditions
- Myeloma, Plasma-Cell, Myeloma-Multiple, Myelomatosis
- Trial name
- NCT01239368
- Testing
- Adoptive Immunotherapy, Rapamycin-Generated Autologous Th1/Tc1 Cells (modified primary human T cells), Th1/Tc1 Rapa Cell Therapy
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Sudden Cardiac Arrest
The Jewel IDE Study
The Jewel IDE Study: A Clinical Evaluation of the Jewel P-WCD in Subjects at High Risk for Sudden Cardiac Arrest. ("JEWEL")
- Trial name
- NCT05201495
- Testing
- Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)
- Where
- 30 sites in United States
- Volunteers
- 322 people
- Sponsor
- Element Science, Inc.
Cardiovascular Diseases
A Study of Evacetrapib in High-Risk Vascular Disease
The purpose of the ACCELERATE study is to evaluate the efficacy and safety of evacetrapib in participants with high-risk vascular disease (HRVD).
- Trial name
- ACCELERATE (NCT01687998)
- Testing
- Evacetrapib
- Where
- 444 sites in United States, Argentina and 35 more
- Volunteers
- 12,092 people
- Sponsor
- Eli Lilly and Company
Preeclampsia, Obstetric Labor Complications
Pravastatin to Prevent Preeclampsia
This study is a double-blind randomized placebo-controlled trial of 1,550 high-risk women to assess whether daily treatment with pravastatin administered early in pregnancy reduces the rate of a composite outcome of preeclampsia…
- Conditions
- Preeclampsia, Obstetric Labor Complications, Hypertension in Pregnancy
- Trial name
- Pravastatin (NCT03944512)
- Testing
- Pravastatin
- Where
- 12 sites in United States
- Volunteers
- 102 people
- Sponsor
- The George Washington University Biostatistics Center
Elevated Cardiac Risk, Coronary Arteries Disease Risk
Cardiovascular Safety of Xenon in General Anaesthesia, in Patient With Cardiovascular Risk in Non Cardiac Surgery
The Primary Objective is to show non inferiority in cardiac safety (i.e myocardial necrosis-MN- assessed by positive cardiac Troponin I -cTnI- ultrasensitive assay) of a Xenon based general anesthesia procedure in patients with…
- Trial name
- CARVASAXe (NCT01120405)
- Testing
- Xenon, Sevoflurane
- Where
- 13 sites in France
- Volunteers
- 600 people
- Sponsor
- Air Liquide Santé International
Cardiovascular Disease, High Cardiovascular Risk
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in overweight and obese subjects with cardiovascular (CV) disease and/or multiple CV risk factors.
- Conditions
- Cardiovascular Disease, High Cardiovascular Risk, Obesity, Overweight
- Trial name
- CAMELLIA-TIMI (NCT02019264)
- Testing
- Lorcaserin hydrochloride
- Where
- 499 sites in United States, Australia and 6 more
- Volunteers
- 14,673 people
- Sponsor
- Eisai Inc.
Multiple Myeloma
Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
To assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-11 in patients with high-risk myeloma who have residual disease following induction therapy.
- Trial name
- NCT04436029
- Testing
- Descartes 11
- Where
- 4 sites in United States
- Volunteers
- 5 people
- Sponsor
- Cartesian Therapeutics
Paroxysmal Atrial Fibrillation
Oral Anticoagulation Therapy Pilot Study
The objective of this study is to determine the safety of discontinuing oral anticoagulation therapy in high risk patients who have had a successful cardiac ablation and remain AF recurrence free for 3 months post ablation.
- Trial name
- OAT (NCT01959425)
- Testing
- Off OAT Group (Test), On OAT Group (Control)
- Volunteers
- 80 people
- Sponsor
- Biosense Webster, Inc.
Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia
Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)
This study is a Phase II, placebo-controlled, double-blind, randomized trial in 480 participants with atherosclerotic cardiovascular disease (ASCVD) or ASCVD-risk equivalents (for example, diabetes and familial…
- Conditions
- Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia, Diabetes
- Trial name
- ORION-1 (NCT02597127)
- Testing
- ALN-PCSSC, Normal Saline
- Where
- 54 sites in United States, Canada and 3 more
- Volunteers
- 501 people
- Sponsor
- The Medicines Company